BRIEF-Allurion Shifts Strategy Toward Low-Dose GLP-1 Combos, Muscle Health and US Entry

Reuters
Aug 05
BRIEF-Allurion Shifts <a href="https://laohu8.com/S/MSTR">Strategy</a> Toward Low-Dose GLP-1 Combos, Muscle Health and US Entry

Aug 5 (Reuters) - Allurion Technologies Inc ALUR.N:

  • ALLURION ANNOUNCES NEW STRATEGIC DIRECTION WITH INCREASING FOCUS ON LOW-DOSE GLP-1 COMBINATION THERAPY, MUSCLE MASS MAINTENANCE, AND US MARKET ENTRY

  • ALLURION TECHNOLOGIES INC - EXPECTS Q2 2025 REVENUE OF $3 MILLION, LOSS OF $7 MILLION

Source text: ID:nBw9FqVV1a

Further company coverage: ALUR.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10